Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb

Bristol Myers Squibb to leverage Repare’s proprietary SNIPRx® synthetic lethal discovery platform to identify multiple oncology drug candidates $65 million upfront payment including $15 million in equity investment Repare Therapeutics eligible to receive development, regulatory and commercial milestones and royalties Cambridge, MA & Montreal, QC, May 26, 2020 (BUSINESS WIRE) — Repare Therapeutics Inc. (“Repare”), a…

Repare Therapeutics Appoints Steve Forte as CFO and Samarth Kulkarni to its Board of Directors

Cambridge, MA & Montreal, QC – Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, announced today that it has made two additions to its leadership team and Board of Directors. Steve Forte, is appointed as Executive Vice President &…